Cargando…

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease

BACKGROUND: Despite major advances in prevention and treatment, coronary artery disease (CAD) remains the leading cause of death worldwide. Whereas many sources of data are available on the epidemiology of acute coronary syndromes, fewer datasets reflect the contemporary management and outcomes of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorbets, Emmanuel, Greenlaw, Nicola, Ferrari, Roberto, Ford, Ian, Fox, Kim M., Tardif, Jean‐Claude, Tendera, Michal, Steg, Philippe Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2017
Materias:	Trial Designs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697615/ https://www.ncbi.nlm.nih.gov/pubmed/28561986 http://dx.doi.org/10.1002/clc.22730

Ejemplares similares

Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry
por: Fauchier, Laurent, et al.
Publicado: (2015)

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
por: Steg, Ph Gabriel, et al.
Publicado: (2012)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2018)

Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry
por: Sorbets, Emmanuel, et al.
Publicado: (2020)

Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease
por: Steg, Ph. Gabriel, et al.
Publicado: (2012)

Use of risk scores to identify lower and higher risk subsets among COMPASS‐eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry
por: Darmon, Arthur, et al.
Publicado: (2020)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Simple risk models to predict cardiovascular death in patients with stable coronary artery disease
por: Ford, Ian, et al.
Publicado: (2020)

Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2019)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study
por: Mesnier, Jules, et al.
Publicado: (2021)

β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study
por: Sorbets, Emmanuel, et al.
Publicado: (2019)

Design and rationale of the North Indian ST‐Segment Elevation Myocardial Infarction Registry: A prospective cohort study
por: Arora, Sameer, et al.
Publicado: (2019)

Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry
por: Pereira, Naveen L., et al.
Publicado: (2021)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry
por: Berman, Adam N., et al.
Publicado: (2020)

EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study
por: Picard, Fabien, et al.
Publicado: (2019)

Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial
por: Ducrocq, Gregory, et al.
Publicado: (2021)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
por: Berry, Colin, et al.
Publicado: (2013)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Design and Rationale of the PRAGUE‐12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation
por: Straka, Zbyněk, et al.
Publicado: (2012)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients
por: Zeng, Jianping, et al.
Publicado: (2021)

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
por: Bain, Stephen C., et al.
Publicado: (2018)

Drug‐coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET‐SMALL 2
por: Gilgen, Nicole, et al.
Publicado: (2018)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial
por: Lukhna, Kishal, et al.
Publicado: (2021)

Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)
por: Yndigegn, Troels, et al.
Publicado: (2022)

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
por: Kirchhof, Paulus, et al.
Publicado: (2017)

Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study()
por: Moody, William E., et al.
Publicado: (2014)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial
por: Vermeer, Jasper, et al.
Publicado: (2023)

Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy
por: Haghikia, Arash, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5aicbcik9918uq687phaphl4kr